Request Demo
Last update 07 Jun 2025
Adalimumab biosimilar(Shandong Danhong Pharmaceutical Co., Ltd.)
Last update 07 Jun 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms 重组抗肿瘤坏死因子-α（TNF-α）全人源单克隆抗体（山东丹红）, BC-002 |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 26792L
The sequence is quoted from: *****
Sequence Code 88699H
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Adalimumab biosimilar(Shandong Danhong Pharmaceutical Co., Ltd.)CTR20201600
一项多中心、随机、双盲、阳性药平行对照，比较BC002（重组抗肿瘤坏死因子-α全人源单克隆抗体注射液）和原研药修美乐®皮下注射治疗活动性强直性脊柱炎有效性、安全性和药代动力学的III期临床试验
[Translation] A multicenter, randomized, double-blind, active-drug parallel-controlled Phase III clinical trial comparing the efficacy, safety, and pharmacokinetics of BC002 (recombinant anti-tumor necrosis factor-α fully human monoclonal antibody injection) and the original drug Humira® subcutaneous injection in the treatment of active ankylosing spondylitis
CTR20190678
健康男性进行的三中心、随机、盲法、平行对照设计，BC002与修美乐单次给药药代动力学比对研究和安全性研究
[Translation] A three-center, randomized, blinded, parallel controlled study in healthy men to compare the pharmacokinetic and safety of BC002 and Humira in a single dose
100 Clinical Results associated with Adalimumab biosimilar(Shandong Danhong Pharmaceutical Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Adalimumab biosimilar(Shandong Danhong Pharmaceutical Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Adalimumab biosimilar(Shandong Danhong Pharmaceutical Co., Ltd.)
Login to view more data
100 Deals associated with Adalimumab biosimilar(Shandong Danhong Pharmaceutical Co., Ltd.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ankylosing Spondylitis | Phase 3 | China | 29 Dec 2020 | |
| Rheumatoid Arthritis | Phase 1 | China | 18 Jun 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free